Crispr Therapeutics shares tumble after significant earnings miss
Phillips 66 (NYSE:PSX) Director Michael A. Heim reported purchasing 1,000 shares of the company’s common stock on July 30, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at a price of $125.97, totaling $125,970. The purchase price represents a premium to the current trading price of $119.54, with InvestingPro analysis indicating the stock is currently undervalued. The $48.3 billion market cap company maintains a "Fair" Financial Health Score of 2.05 out of 3 and offers a 4% dividend yield.
Following the transaction, Heim directly owns 12,043 shares of Phillips 66, which includes 1,043 Restricted Stock Units that convert to Phillips 66 common stock on a 1-for-1 basis
In other recent news, Phillips 66 reported robust earnings for the second quarter of 2025, highlighting strong refining utilization and strategic shareholder returns. The company posted adjusted earnings of $973 million, or $2.38 per share, alongside an operating cash flow of $1.9 billion, excluding working capital. UBS has responded to these results by raising its price target for Phillips 66 to $143, maintaining a Buy rating and citing the company’s competitive business model and operational improvements. Similarly, TD Cowen increased its price target to $134, also maintaining a Buy rating due to Phillips 66’s strong refining performance and its lowest operational expenses since 2021. These developments underscore the company’s operational efficiency and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.